The Eden Prairie, Minn.-based company said it plans to offer 2.2 million shares of its common stock at $2.12 per share. The offering includes a 45-day underwriter’s option for an additional 332,239 shares at the public offering price.
Ladenburg Thalmann & Co are acting as sole book-running manager for the offering, with Dawson James Securities acting as co-manager, according to a press release. The offering is expected to close July 3.
CHF Solutions said it plans to use net proceeds for general corporate purposes, including the expansion of its field sales force and commercial organization.
In May, CHF Solutions saw shares fall after the heart-focused medical device maker missed expectations on Wall Street with its first quarter earnings results.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.